Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImClone Systems has announced that a Phase I clinical trial of IMC-A12, a fully human, IgG1 anti-insulin-like growth factor-1 receptor monoclonal antibody, plus the mTOR inhibitor temsirolimus in patients with advanced solid malignancies and lymphoma has opened for patient enrollment.
Subscribe to our email newsletter
This study is a component of an initial stage of at least 10 Phase I and II clinical trials of IMC-A12 sponsored by the cancer therapy evaluation program of the division of cancer treatment and diagnosis at the National Cancer Institute (NCI), to commence patient enrollment. ImClone announced the selection of these proposals by NCI in September 2007.
Eric Rowinsky, chief medical officer and executive vice president of ImClone, said: “This NCI-sponsored IMC-A12 trial is based on preclinical evidence that the mTOR and IGF-1R growth and survival signaling pathways are intimately linked and, therefore, the combination of IMC-A12 and temsirolimus may be an ideal means to optimize treatment.”